XXXX response and pre-treatment EEG-is there some kind of relationship.

@entity1 @entity1088 @entity161
BACKGROUND: @entity1088 has been used widely in the management of treatment-resistant @entity161 . The present study aims at determining whether pre-treatment electroencephalography (EEG) abnormalities would serve as a marker for response to @entity1088 treatment. SUBJECTS AND METHODS: This was a cross-sectional study done in a tertiary care center in Mumbai where @entity1 diagnosed with @entity161 using DSM-IV criteria and resistant @entity161 using Kane criteria were assessed using EEG prior to starting @entity1088 treatment. They were rated for symptomatic improvement using the Positive and Negative Syndrome Scale (PANSS) along with Clinical Global Improvement for Severity (CGI-S). The results were statistically analysed and presented. RESULTS: 55 out of the 80 @entity1 in the study showed baseline EEG abnormalities. The mean duration of illness in the @entity1 were 2.65 years. Slow wave and background EEG abnormalities were common in pre-treatment EEG. 36.4% @entity1 in the study showed clinical response. @entity1 with negative symptoms and baseline EEG abnormalities showed better response. CONCLUSIONS: The study was circumscribed and had many limitations due to a small sample size. The relation between pre-treatment EEG abnormalities and @entity1088 response could not be statistically correlated and it could not be ascertained to be a marker for response to @entity1088 therapy.
